Recombinant proteins

Defining Moments Canada: Insulin100 – Manufacturing Hope

Retrieved on: 
Friday, February 19, 2021
Clinical medicine, Branches of biology, Hormones, Peptide hormones, Recombinant proteins, Insulin, Hope, British Columbia, Canadas, Toronto

Join Defining Moments Canada to explore a century of insulins far-reaching legacy and the impact the discovery continues to have on Canadians today.

Key Points: 
  • Join Defining Moments Canada to explore a century of insulins far-reaching legacy and the impact the discovery continues to have on Canadians today.
  • TORONTO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Defining Moments Canada/Moments Dterminants Canada has entered the second year of its Insulin100: Inspiration and Innovation commemorative project and is excited to share John Lorincs newest piece, Manufacturing Hope , which examines the discovery of insulins continued legacy in honour of the centennial (originally published in Canadas History Magazine .)
  • Read Lorincs entire article, titled Manufacturing Hope , and learn more about the discovery of insulin and its complex legacy at DefiningMomentsCanada.ca .
  • In 2020, Defining Moments Canada led the national digital commemoration for VEDay75 , in partnership with Veterans Affairs Canada.

GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology

Retrieved on: 
Thursday, February 18, 2021
World Federation of Hemophilia, Coagulation system, Haemophilia, Recombinant proteins, Health, Branches of biology

Neoletix has chosen GenScript ProBio to help develop and manufacture NX-01 for its upcoming clinical trial.

Key Points: 
  • Neoletix has chosen GenScript ProBio to help develop and manufacture NX-01 for its upcoming clinical trial.
  • Hemophilia A is most commonly treated using FVIII replacement therapy, in which FVIII can be derived either from human blood or produced recombinantly.
  • According to the National Bureau of Statistics and the World Federation of Hemophilia, there are 140,000 hemophilia patients in China.
  • "We are partnering with GenScript ProBio, one of the leading CDMO companies in China, to help us manufacture NX-01.

Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review

Retrieved on: 
Wednesday, February 17, 2021
Drugs, Health care, Life sciences, Amgen, Recombinant proteins, Biotechnology, Immunosuppressants, TNF inhibitors, Biosimilar, Adalimumab, Pegfilgrastim, AbbVie

If approved, Coherus plans to launch the adalimumab biosimilar in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie.

Key Points: 
  • If approved, Coherus plans to launch the adalimumab biosimilar in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie.
  • In February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody, in the United States and Canada.
  • Coherus strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business.
  • Coherus markets UDENYCA (pegfilgrastim-cbqv) inthe United Statesand through 2023 expects to launch biosimilars of Humira, Avastin and Lucentis, if approved.

United States Insulin Syringes Market Report 2020-2027: Reimbursement, Market Dynamics, Opportunities, Future Roadmap, Competitive Outlook

Retrieved on: 
Tuesday, February 16, 2021
Clinical medicine, Medicine, Branches of biology, Medical equipment, Peptide hormones, Recombinant proteins, Drug paraphernalia, Insulin, Syringe

"U.S. Insulin Syringes Market Prospect, Share, Development, Growth and Demand Forecast to 2027" present an in-depth assessment of the United States' insulin syringes market dynamics, opportunities, future roadmap, competitive outlook and discusses foremost trends.

Key Points: 
  • "U.S. Insulin Syringes Market Prospect, Share, Development, Growth and Demand Forecast to 2027" present an in-depth assessment of the United States' insulin syringes market dynamics, opportunities, future roadmap, competitive outlook and discusses foremost trends.
  • The report gives the most up-to-date industry statistics in the real market place situation and future outlook in the United States insulin syringes market.
  • The report provides a clear insight into modern-day and future traits of the United States insulin syringes market.
  • The report concludes with the profiles of key players in the United States insulin syringes market.

United States Insulin Syringes Market Report 2020 - Prospect, Share, Development, Growth and Demand Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 15, 2021
Diabetes, Health, Medical Supplies, Clinical medicine, Medicine, Branches of biology, Medical equipment, Drug paraphernalia, Peptide hormones, Recombinant proteins, Syringe, Insulin

"U.S. Insulin Syringes Market Prospect, Share, Development, Growth and Demand Forecast to 2027" present an in-depth assessment of the United States' insulin syringes market dynamics, opportunities, future roadmap, competitive outlook and discusses foremost trends.

Key Points: 
  • "U.S. Insulin Syringes Market Prospect, Share, Development, Growth and Demand Forecast to 2027" present an in-depth assessment of the United States' insulin syringes market dynamics, opportunities, future roadmap, competitive outlook and discusses foremost trends.
  • The report gives the most up-to-date industry statistics in the real market place situation and future outlook in the United States insulin syringes market.
  • The report provides a clear insight into modern-day and future traits of the United States insulin syringes market.
  • The report also explores the exhaustive description of growth drivers and inhibitors of the United States insulin syringes market.

Global Insulin Pen Market Report 2020-2025: Market is Expected to Surpass US$ 35 Billion

Retrieved on: 
Wednesday, February 10, 2021
Clinical medicine, Branches of biology, Medicine, Peptide hormones, Recombinant proteins, Insulin, Injector pen, Insulin pump, Intensive insulin therapy

Global Insulin Pen Market is expected to surpass US$ 35 Billion by the end of the year 2025.

Key Points: 
  • Global Insulin Pen Market is expected to surpass US$ 35 Billion by the end of the year 2025.
  • The disposable insulin pen is also called prefilled insulin pen.
  • Smart insulin pen is the Bluetooth enabled insulin pen that records the time/date of insulin injections that have been delivered.
  • The recent addition to the pack Smart insulin pen is also known as a "connected" insulin pen.

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats

Retrieved on: 
Tuesday, February 9, 2021
General Health, Diabetes, Consumer, Health, Pets, Clinical medicine, Branches of biology, Hormones, Peptide hormones, Recombinant proteins, Insulin, Intellectual property law, Royalty payment, Akston Biosciences, Dechra

The supply agreement calls for Akston to be the exclusive manufacturer of the product to be marketed by Dechra.

Key Points: 
  • The supply agreement calls for Akston to be the exclusive manufacturer of the product to be marketed by Dechra.
  • The multi-million-dollar licensing and development agreement includes payments to Akston on signing, for development milestones, and a royalty on sales.
  • In 2019, the two companies signed a licensing and supply agreement for AKS-321d, a once-a-week insulin therapy for dogs.
  • Dechra has proven to be a strong and valued partner in the commercialization of our ultra-long-acting insulin technology for pets.

Insulet to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 8, 2021
Biotechnology, Diabetes, Health, Medical devices, Clinical medicine, Medicine, Branches of biology, Insulin pump, Peptide hormones, Recombinant proteins, Insulin, Diabetes, Dexcom

Replays of the webcasts will also be available following the events.

Key Points: 
  • Replays of the webcasts will also be available following the events.
  • Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Global Biosimilar Growth Hormones Market Report 2020: Market is Expected to Recover in 2023, Growing at a CAGR of 9.07%

Retrieved on: 
Friday, February 5, 2021
Growth hormones, Life sciences, Recombinant proteins, Hormones, Medicine, Biosimilar, Biotechnology, Drugs, Growth hormone

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The biosimilar growth hormone market consists of sales of Somatropin or human growth hormone (HGH) and related services by entities (organizations, sole traders and partnerships) that manufacture growth hormones.
  • The growing number of children suffering from growth hormone deficiency is driving the growth of the global biosimilar growth hormone market.
  • Global Biosimilar Growth Hormones Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.

Global Filgrastim Biosimilars Market Report 2020: COVID-19 Impacts, Growth and Changes - 2015-2019, 2023F, 2025F, 2030F

Retrieved on: 
Friday, February 5, 2021
Life sciences, Biotechnology, Health care, Biosimilar, Drugs, Amgen, Recombinant proteins, Filgrastim

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate (CAGR) of -12.93%.
  • The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars.
  • Hence, the government initiatives for the development of biosimilars aids in the increased production and awareness which in turn supports the growth of the filgrastim biosimilars market.